Skip to content
Menu

ProKidney Corp. PROK

Full chart Compare
Set alert

Price alert · PROK

All alert types
1.04 USD -0.02 (-1.89%)

Regular-session close

1.03 -0.01 -0.94%

After hours · Nov 20, 7:25 PM ET

1.02 Day range 1.08
1.04 52-week range 2.57
YTD
-53.57%
1 year
-50.24%

5D -0.05 (-4.42%)

1.051.10FriMonTueWedThu1.08
Market cap
415.21M
Revenue (ttm)
527.00K
EPS (ttm)
-0.61
Shares out
134.99M
Forward P/E
-5.33
YTD return
-53.57%
1-year return
-50.24%
50-day average
2.68
Volume
1.90M
Avg volume
1.43M
Open
1.03
Previous close
1.06
Day's range
1.02 – 1.08
52-week range
1.04 – 2.57
Beta
1.79
Price target
5.83 (+460.9%)

Key statistics

200-day average
1.62
Enterprise value
1.42B
Price / sales
1518.88
Free cash flow
-112.58M
Total cash
294.73M
Total debt
4.42M
Return on equity
-40.52%
Short % of float
8.70%

Fundamental scorecard

4 of 25 checks passed on PROK’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PROK Revenue — quarterly 174.00K
PROK Net income — quarterly -35.59M
PROK EPS — quarterly -0.17

Upgrades / downgrades

PROK analyst upgrades and downgrades
DateFirmActionFromTo
Jul 15, 2025UBSmainBuyBuy
Jul 14, 2025GuggenheimmainBuyBuy
Jul 9, 2025CitigroupmainBuyBuy
Jun 30, 2025B of A SecuritiesdownNeutralUnderperform
Sep 30, 2024JP Morganinit—Neutral
Sep 10, 2024Guggenheiminit—Buy

About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on PROK — it syncs with the Stock Master app.

Insider holders

PROK insider holders
InsiderRelationLatest transactionDateShares held
CONTROL EMPRESARIAL DE CAPITALES, S.A. DE C.V.Beneficial Owner of more than 10% of a Class of SecurityPurchaseApr 21, 202510,724,100
GIROLAMO TODD C. J.D.OfficerConversion of Exercise of derivative securityJul 30, 2024163,856
LEGORRETA PABLO GDirector and Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJun 2, 20250
PALIHAPITIYA CHAMATHBeneficial Owner of more than 10% of a Class of SecuritySaleNov 16, 20230
PEREIRA BRIAN J GDirectorConversion of Exercise of derivative securityFeb 3, 20250
WEBER DARIN J.OfficerSaleJul 7, 20250

Institution ownership

PROK institution ownership
Holder% heldSharesValueReported
Suvretta Capital Management, LLC9.14%12,341,26633.57MJun 29, 2025
Morgan Stanley4.44%5,987,54116.29MJun 29, 2025
Bleichroeder LP1.48%2,000,0005.44MJun 29, 2025
Blackrock Inc.1.31%1,764,6074.80MJun 29, 2025
JPMORGAN CHASE & CO1.24%1,668,6424.54MJun 29, 2025
Vanguard Group Inc1.16%1,567,8684.26MJun 29, 2025

Fund ownership

PROK fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.02%1,375,4533.74MJun 29, 2025
Brighthouse Funds Trust I-Morgan Stanley Discovery Portfolio0.63%849,3502.31MJun 29, 2025
Morgan Stanley Insight Fund0.59%795,2602.16MJun 29, 2025
MORGAN STANLEY INSTITUTIONAL FUND TRUST-Discovery Portfolio0.54%733,3051.99MJun 29, 2025
VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund0.42%571,7951.56MMay 30, 2025
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund0.36%492,0061.34MJul 30, 2025